GONADAL DYSGENESIS AND HYPOPITUITARISM (DELETION-INDUCED HEMIZYGOSITY).

K. Becker,A. Albert,J. Paris

1963-10-09

Abstract:

What problem does this paper attempt to address?

The 'squeaky wheel' and health care policy.

G. Friedell

DOI: https://doi.org/10.1001/JAMA.1991.03460240096035

1991-06-26

Abstract:ESTABLISHING public policy for health care is difficult at best. But when policy decisions result primarily from the application of the "squeaky wheel" principle, the difficulty is compounded. Decisions are then more likely to deal with the concerns of a small group of individuals rather than the broader interests of society, with private patient care rather than public health needs, and with short-term expenditures rather than long-term savings. A story on the front page of the New York Times on November 12, 1990, focused my attention clearly on an issue that exemplifies this problem. The story reported, "The Blue Cross and Blue Shield Association has agreed to pay a share of the costs of a clinical study of an experimental treatment for advanced breast cancer." The association would expend at least $10 million during the 3-to 4-year study of 1200 women who will undergo autologous bone marrow transplantation in conjunction
Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia

Alessandra Ludovico,Oscar Moran,Debora Baroni

DOI: https://doi.org/10.3390/ijms231911396

2022-09-27

Abstract:Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a plasma membrane protein expressed on the apical surface of secretory epithelia of the airways. In the airways, defective or absent function of the CFTR protein determines abnormalities of chloride and bicarbonate secretion and, in general, of the transepithelial homeostasis that lead to alterations of airway surface liquid (ASL) composition and properties. The reduction of ASL volume impairs ciliary beating with the consequent accumulation of a sticky mucus. This situation prevents normal mucociliary clearance, favoring the survival and proliferation of bacteria and contributing to the genesis of the CF pulmonary disease. We explored the potential of some CFTR modulators, namely ivacaftor, tezacaftor, elexacaftor and their combination KaftrioTM, capable of partially recovering the basic defects of the CFTR protein, to ameliorate the transepithelial fluid transport and the viscoelastic properties of the mucus when used singly or in combination. Primary human bronchial epithelial cells obtained from CF and non-CF patients were differentiated into a mucociliated epithelia in order to assess the effects of correctors tezacaftor, elexacaftor and their combination with potentiator ivacaftor on the key properties of ASL, such as fluid reabsorption, viscosity, protein content and pH. The treatment of airway epithelia bearing the deletion of a phenylalanine at position 508 (F508del) in the CFTR gene with tezacaftor and elexacaftor significantly improved the pericilial fluid composition, reducing the fluid reabsorption, correcting the ASL pH and reducing the viscosity of the mucus. KaftrioTM was more effective than single modulators in improving all the evaluated parameters, demonstrating once more that this combination recently approved for patients 6 years and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene represents a valuable tool to defeat CF.
Perceptual Comparisons with Pictures and Environmental Sounds

P. Goolkasian,Alexandra Stubblefield

Abstract:Perceptual Comparisons with Pictures and Environmental Sounds Paula Goolkasian UNC Charlotte Alexandra Stubblefield UNC Charlotte Abstract: This research involves perceptual comparisons with cues that vary in one of four ways (picture, sound, spoken word or printed word) and with targets that are either pictures or environmental sounds. Students were required to match cue-target pairs and determine whether the 2 successive events represented features drawn from the same item. Both the perceptual/linguistic format and the modality of the cue influenced responses to pictures and environmental sounds, but the cue type effects were qualified by same/different response type and with picture targets by left or right presentation location. These results provide some additional evidence of processing asymmetry when pictures are directed to either the right or left hemisphere, as well as for some asymmetries in cross modal cueing. Implications of these findings for theories of multisensory processing and models of object recognition are discussed.
A promoter-dependent upstream activator augments CFTR expression in diverse epithelial cell types

Giuliana C Coatti,Nirbhayaditya Vaghela,Pulak Gillurkar,Shih-Hsing Leir,Ann Harris

DOI: https://doi.org/10.1016/j.bbagrm.2024.195031

Abstract:The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes an anion-selective channel found in epithelial cell membranes. Mutations in CFTR cause cystic fibrosis (CF), an inherited disorder that impairs epithelial function in multiple organs. Most men with CF are infertile due to loss of intact genital ducts. Here we investigated a novel epididymis-selective cis-regulatory element (CRE), located within a peak of open chromatin at -9.5 kb 5' to the CFTR gene promoter. Activation of the -9.5 kb CRE alone by CRISPRa had no impact on CFTR gene expression. However, CRISPRa co-activation of the -9.5 kb CRE and the CFTR gene promoter in epididymis cells significantly augmented CFTR mRNA and protein expression when compared to promoter activation alone. This increase was accompanied by enhanced chromatin accessibility at both sites. Furthermore, the combined CRISPRa strategy activated CFTR expression in other epithelial cells that lack open chromatin at the -9.5 kb site and in which the locus is normally inactive. However, the -9.5 kb CRE does not function as a classical enhancer of the CFTR promoter in transient reporter gene assays. These data provide a novel mechanism for activating/augmenting CFTR expression, which may have therapeutic utility for mutations that perturb CFTR transcription.
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis

Hermann Bihler,Andrey Sivachenko,Linda Millen,Priyanka Bhatt,Amita Thakerar Patel,Justin Chin,Violaine Bailey,Isaac Musisi,André LaPan,Normand E Allaire,Joshua Conte,Noah R Simon,Amalia S Magaret,Karen S Raraigh,Garry R Cutting,William R Skach,Robert J Bridges,Philip J Thomas,Martin Mense,Normand E. Allaire,Noah R. Simon,Amalia S. Magaret,Karen S. Raraigh,Garry R. Cutting,William R. Skach,Robert J. Bridges,Philip J. Thomas

DOI: https://doi.org/10.1016/j.jcf.2024.02.006

IF: 5.527

2024-02-24

Journal of Cystic Fibrosis

Abstract:Background In 2017, the US Food and Drug Administration initiated expansion of drug labels for the treatment of cystic fibrosis (CF) to include CF transmembrane conductance regulator (CFTR) gene variants based on in vitro functional studies. This study aims to identify CFTR variants that result in increased chloride (Cl − ) transport function by the CFTR protein after treatment with the CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). These data may benefit people with CF (pwCF) who are not currently eligible for modulator therapies. Methods Plasmid DNA encoding 655 CFTR variants and wild-type (WT) CFTR were transfected into Fisher Rat Thyroid cells that do not natively express CFTR. After 24 h of incubation with control or TEZ and ELX, and acute addition of IVA, CFTR function was assessed using the transepithelial current clamp conductance assay. Each variant's forskolin/cAMP-induced baseline Cl − transport activity, responsiveness to IVA alone, and responsiveness to the TEZ/ELX/IVA combination were measured in three different laboratories. Western blots were conducted to evaluate CFTR protein maturation and complement the functional data. Results and conclusions 253 variants not currently approved for CFTR modulator therapy showed low baseline activity (<10 % of normal CFTR Cl − transport activity). For 152 of these variants, treatment with ELX/TEZ/IVA improved the Cl − transport activity by ≥10 % of normal CFTR function, which is suggestive of clinical benefit. ELX/TEZ/IVA increased CFTR function by ≥10 percentage points for an additional 140 unapproved variants with ≥10 % but <50 % of normal CFTR function at baseline. These findings significantly expand the number of rare CFTR variants for which ELX/TEZ/IVA treatment should result in clinical benefit.

respiratory system
Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

Filipa C. Ferreira,Camilla D. Buarque,Miquéias Lopes-Pacheco

DOI: https://doi.org/10.3390/molecules29040821

IF: 4.6

2024-02-11

Molecules

Abstract:The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells. The discovery and subsequent development of CFTR modulators—small molecules acting on the basic molecular defect in CF—have revolutionized the standard of care for people with CF (PwCF), thus drastically improving their clinical features, prognosis, and quality of life. Currently, four of these drugs are approved for clinical use: potentiator ivacaftor (VX-770) alone or in combination with correctors lumacaftor, (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). Noteworthily, the triple combinatorial therapy composed of ivacaftor, tezacaftor, and elexacaftor constitutes the most effective modulator therapy nowadays for the majority of PwCF. In this review, we exploit the organic synthesis of ivacaftor, tezacaftor, and elexacaftor by providing a retrosynthetic drug analysis for these CFTR modulators. Furthermore, we describe the current understanding of the mechanisms of action (MoA's) of these compounds by discussing several studies that report the key findings on the molecular mechanisms underlying their action on the CFTR protein.

chemistry, multidisciplinary,biochemistry & molecular biology
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Fredrick Van Goor,Sabine Hadida,Peter D. J. Grootenhuis,Bill Burton,Dong Cao,Tim Neuberger,Amanda Turnbull,Ashvani Singh,John Joubran,Anna Hazlewood,Jinglan Zhou,Jason McCartney,Vijayalaksmi Arumugam,Caroline Decker,Jennifer Yang,Chris Young,Eric R. Olson,Jeffery J. Wine,Raymond A. Frizzell,Melissa Ashlock,Paul Negulescu

DOI: https://doi.org/10.1073/pnas.0904709106

IF: 11.1

2009-11-03

Proceedings of the National Academy of Sciences

Abstract:Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung. Most CF mutations either reduce the number of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both. There are currently no approved therapies that target CFTR. Here we describe the in vitro pharmacology of VX-770, an orally bioavailable CFTR potentiator in clinical development for the treatment of CF. In recombinant cells VX-770 increased CFTR channel open probability (P o ) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl − secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈10-fold, to ≈50% of that observed in HBE isolated from individuals without CF. Furthermore, VX-770 reduced excessive Na + and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures. These results support the hypothesis that pharmacological agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.

multidisciplinary sciences
Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells

Chiara De Santi,Elena Fernández Fernández,Rachel Gaul,Sebastian Vencken,Arlene Glasgow,Irene K Oglesby,Killian Hurley,Finn Hawkins,Nilay Mitash,Fangping Mu,Rana Raoof,David C Henshall,Meritxell B Cutrona,Jeremy C Simpson,Brian J Harvey,Barry Linnane,Paul McNally,Sally Ann Cryan,Ronan MacLoughlin,Agnieszka Swiatecka-Urban,Catherine M Greene

DOI: https://doi.org/10.1016/j.ymthe.2020.02.001

2020-04-08

Abstract:MicroRNAs that are overexpressed in cystic fibrosis (CF) bronchial epithelial cells (BEC) negatively regulate CFTR and nullify the beneficial effects of CFTR modulators. We hypothesized that it is possible to reverse microRNA-mediated inhibition of CFTR using CFTR-specific target site blockers (TSBs) and to develop a drug-device combination inhalation therapy for CF. Lead microRNA expression was quantified in a series of human CF and non-CF samples and in vitro models. A panel of CFTR 3' untranslated region (UTR)-specific locked nucleic acid antisense oligonucleotide TSBs was assessed for their ability to increase CFTR expression. Their effects on CFTR activity alone or in combination with CFTR modulators were measured in CF BEC models. TSB encapsulation in poly-lactic-co-glycolic acid (PLGA) nanoparticles was assessed as a proof of principle of delivery into CF BECs. TSBs targeting the CFTR 3' UTR 298-305:miR-145-5p or 166-173:miR-223-3p sites increased CFTR expression and anion channel activity and enhanced the effects of ivacaftor/lumacaftor or ivacaftor/tezacaftor in CF BECs. Biocompatible PLGA-TSB nanoparticles promoted CFTR expression in primary BECs and retained desirable biophysical characteristics following nebulization. Alone or in combination with CFTR modulators, aerosolized CFTR-targeting TSBs encapsulated in PLGA nanoparticles could represent a promising drug-device combination therapy for the treatment for CFTR dysfunction in the lung.
Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure

Heidi J Nick,Pamela L Zeitlin,Sangya Yadav,Preston E Bratcher

DOI: https://doi.org/10.1038/s41598-021-02044-1

2021-11-19

Abstract:Quantitation of CFTR function in vitro is commonly performed by acutely stimulating then inhibiting ion transport through CFTR and measuring the resulting changes in transepithelial voltage (Vte) and current (ISC). While this technique is suitable for measuring the maximum functional capacity of CFTR, it may not provide an accurate estimate of in vivo CFTR activity. To test if CFTR-mediated ion transport could be measured in the absence of acute CFTR stimulation, primary airway epithelia were analyzed in an Ussing chamber with treatment of amiloride followed by CFTR(inh)-172 without acute activation of CFTR. Non-CF epithelia demonstrated a decrease in Vte and ISC following exposure to CFTR(inh)-172 and in the absence of forskolin/IBMX (F/I); this decrease is interpreted as a measure of spontaneous CFTR activity present in these epithelia. In F508del/F508del CFTR epithelia, F/I-induced changes in Vte and ISC were ~ fourfold increased after treatment with VX-809/VX-770, while the magnitude of spontaneous CFTR activities were only ~ 1.6-fold increased after VX-809/VX-770 treatment. Method-dependent discrepancies in the responses of other CF epithelia to modulator treatments were observed. These results serve as a proof of concept for the analysis of CFTR modulator responses in vitro in the absence of acute CFTR activation. Future studies will determine the usefulness of this approach in the development of novel CFTR modulator therapies.
More Efficient Tagging Systems with Tag Seeding

Vikas Kumar,Daniel Kluver,L. Terveen,J. Riedl

2014-06-16

Abstract:GroupLens Research-Department of Computer Science, University of Minnesota, Twin Cities, USA The authors thank Ting-Yu Wang for his contribution in developing the user interface. Authors would also like to thank Shilad Sen and the rest of GroupLens for their feed- back on the ideas presented in this paper. We also thank the MovieLens community for their responses, feedback and suggestions. This paper is funded by National Science Foundation grant IIS 09-64695.
Molecular characterization and chromosomal localization of mouse Puralpha gene.

V. Muralidharan,L. Cort,E. Meier,E. Blankenhorn,K. Khalili

Journal of Cellular Biochemistry

Abstract:Puralpha is a 39-kDa sequence-specific single-stranded DNA/RNA binding protein with the ability to modulate transcription of several genes containing the Pur element in their promoter region. Human and mouse Puralpha exhibit an extraordinary degree of conservation with only two changes at amino acid residues 49 and 306. A 15-kb genomic clone encompassing the mouse Puralpha gene was isolated by screening the mouse genomic library, using a PCR-amplified fragment from human Puralpha cDNA. Results from sequencing analysis confirmed the isolated genomic clone to be Puralpha and not the other members of the Pur family, including Purbeta. Characterization of the mouse Puralpha gene by restriction analysis/Southern blotting and sequencing revealed that the Puralpha gene contains only one intron within the 5' UTR and the open reading frame was intact. Using chromosomal markers, the Puralpha gene was mapped to chromosome 18 in mouse and rat.
Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome

Kerstin Fentker,Marieluise Kirchner,Matthias Ziehm,Sylvia Niquet,Oliver Popp,Julia Duerr,Laura Schaupp,Jobst Roehmel,Stephanie Thee,Susanne Haemmerling,Olaf Sommerburg,Mirjam Stahl,Simon Y. Graeber,Marcus A. Mall,Philipp Mertins

DOI: https://doi.org/10.1101/2024.10.18.619058

2024-10-18

Abstract:Cystic fibrosis (CF), resulting from a dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR), affects multiple organs through mucus obstruction and differences in secretion. The CFTR modulator drug combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, ETI) has markedly improved clinical symptoms, but its broader molecular and systemic effects remain to be fully elucidated. We employed mass spectrometry-based proteomics to compare the blood proteomes of CF patients treated with the earlier, less effective lumacaftor/ivacaftor (LUM/IVA) combination against those receiving the more potent ELX/TEZ/IVA therapy. Our analysis revealed both specific and common pharmacodynamic signatures associated with inflammation and metabolic processes under each treatment regimen. Notably, ELX/TEZ/IVA therapy exhibited more consistent alterations across patients that were directed towards profiles observed in healthy individuals. Furthermore, by comparing sputum and blood proteomes of ELX/TEZ/IVA treated patients we identified counter directional changes in the pulmonary surfactant-associated protein B, SFTPB, a potential biomarker of lung tissue repair, which also correlated with lung function improvements. This study provides a comprehensive resource that enhances our understanding of CFTR modulator-driven proteome alterations, offering insights to both systemic and local protein regulation in CF. Our findings indicate that ELX/TEZ/IVA promotes broader systemic health improvements, providing critical insights that could shape future therapeutic strategies in CF.

Molecular Biology
Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms

Luyang Cao,Yong Wu,Yanchun Gong,Qingfa Zhou

DOI: https://doi.org/10.1016/j.ejmech.2023.116120

IF: 7.088

2024-01-10

European Journal of Medicinal Chemistry

Abstract:The advent of small molecule modulators targeting the cystic fibrosis transmembrane conductance regulator (CFTR) has revolutionized the treatment of persons with cystic fibrosis (CF) (pwCF). Presently, these small molecule CFTR modulators have gained approval for usage in approximately 90 % of adult pwCF. Ongoing drug development endeavors are focused on optimizing the therapeutic benefits while mitigating potential adverse effects associated with this treatment approach. Based on their mode of interaction with CFTR, these drugs can be classified into two distinct categories: specific CFTR modulators and non-specific CFTR modulators. Specific CFTR modulators encompass potentiators and correctors, whereas non-specific CFTR modulators encompass activators, proteostasis modulators, stabilizers, reader-through agents, and amplifiers. Currently, four small molecule modulators, all classified as potentiators and correctors, have obtained marketing approval. Furthermore, numerous novel small molecule modulators, exhibiting diverse mechanisms of action, are currently undergoing development. This review aims to explore the classification, mechanisms of action, molecular structures, developmental processes, and interrelationships among small molecule CFTR modulators.

chemistry, medicinal
The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells

Raphaël Santinelli,Nathalie Benz,Julie Guellec,Fabien Quinquis,Ervin Kocas,Johan Thomas,Tristan Montier,Chandran Ka,Emilie Luczka-Majérus,Edouard Sage,Claude Férec,Christelle Coraux,Pascal Trouvé

DOI: https://doi.org/10.3390/cells13020185

IF: 6

2024-01-19

Cells

Abstract:Cystic Fibrosis (CF) is present due to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, the most frequent variant being p.phe508del. The CFTR protein is a chloride (Cl-) channel which is defective and almost absent of cell membranes when the p.Phe508del mutation is present. The p.Phe508del-CFTR protein is retained in the endoplasmic reticulum (ER) and together with inflammation and infection triggers the Unfolded Protein Response (UPR). During the UPR, the Activating Transcription Factor 6 (ATF6) is activated with cleavage and then decreases the expression of p.Phe508del-CFTR. We have previously shown that the inhibition of the activation of ATF6 alleviates the p.Phe508del-CFTR defects in cells overexpressing the mutated protein. In the present paper, our aim was to inhibit the cleavage of ATF6, and thus its activation in a human bronchial cell line with endogenous p.Phe508del-CFTR expression and in bronchial cells from patients, to be more relevant to CF. This was achieved by inhibiting the protease MBTP1 which is responsible for the cleavage of ATF6. We show here that this inhibition leads to increased mRNA and p.Phe508del-CFTR expression and, consequently, to increased Cl-efflux. We also explain the mechanisms linked to these increases with the modulation of genes when MBTP1 is inhibited. Indeed, RT-qPCR assays show that genes such as HSPA1B, CEBPB, VIMP, PFND2, MAPK8, XBP1, INSIG1, and CALR are modulated. In conclusion, we show that the inhibition of MBTP1 has a beneficial effect in relevant models to CF and that this is due to the modulation of genes involved in the disease.

cell biology
Potentiation of long-acting β2-agonist and glucocorticoid responses in human airway epithelial cells by modulation of intracellular cAMP

Yechan Kim,Vincent Hou,Ryan D Huff,Jennifer A Aguiar,Spencer Revill,Nicholas Tiessen,Quynh Cao,Matthew S Miller,Mark D Inman,Kjetil Ask,Andrew C Doxey,Jeremy A Hirota

DOI: https://doi.org/10.1186/s12931-021-01862-1

2021-10-19

Abstract:Introduction: Over 300 million people in the world live with asthma, resulting in 500,000 annual global deaths with future increases expected. It is estimated that around 50-80% of asthma exacerbations are due to viral infections. Currently, a combination of long-acting beta agonists (LABA) for bronchodilation and glucocorticoids (GCS) to control lung inflammation represent the dominant strategy for the management of asthma, however, it is still sub-optimal in 35-50% of moderate-severe asthmatics resulting in persistent lung inflammation, impairment of lung function, and risk of mortality. Mechanistically, LABA/GCS combination therapy results in synergistic efficacy mediated by intracellular cyclic adenosine monophosphate (cAMP). Hypothesis: Increasing intracellular cAMP during LABA/GCS combination therapy via inhibiting phosphodiesterase 4 (PDE4) and/or blocking the export of cAMP by ATP Binding Cassette Transporter C4 (ABCC4), will potentiate anti-inflammatory responses of mainstay LABA/GCS therapy. Methods: Expression and localization experiments were performed using in situ hybridization and immunohistochemistry in human lung tissue from healthy subjects, while confirmatory transcript and protein expression analyses were performed in primary human airway epithelial cells and cell lines. Intervention experiments were performed on the human airway epithelial cell line, HBEC-6KT, by pre-treatment with combinations of LABA/GCS with PDE4 and/or ABCC4 inhibitors followed by Poly I:C or imiquimod challenge as a model for viral stimuli. Cytokine readouts for IL-6, IL-8, CXCL10/IP-10, and CCL5/RANTES were quantified by ELISA. Results: Using archived human lung and human airway epithelial cells, ABCC4 gene and protein expression were confirmed in vitro and in situ. LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined. Modulation of cAMP levels had no impact on LABA/GCS modulation of Poly I:C-induced CXCL10/IP-10 or CCL5/RANTES. Conclusion: Modulation of intracellular cAMP levels by PDE4 or ABCC4 inhibition potentiates LABA/GCS efficacy in human airway epithelial cells challenged with viral stimuli. The data suggest further exploration of the value of adding cAMP modulators to mainstay LABA/GCS therapy in asthma for potentiated anti-inflammatory efficacy.
Current landscape of cystic fibrosis gene therapy

Lindsey W. Plasschaert,Kelvin D. MacDonald,Jeffrey S. Moffit

DOI: https://doi.org/10.3389/fphar.2024.1476331

IF: 5.6

2024-10-09

Frontiers in Pharmacology

Abstract:Cystic fibrosis is a life-threatening disease that is caused by mutations in CFTR , a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three decades of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression in vitro and in vivo through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where CFTR needs to be expressed, the most advanced vectors for CFTR delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.

pharmacology & pharmacy
Disabling musculoskeletal pain and its relation to somatization: a community-based postal survey.

K. Palmer,M. Calnan,D. Wainwright,J. Poole,C. O’Neill,A. Winterbottom,C. Watkins,D. Coggon

DOI: https://doi.org/10.1093/OCCMED/KQI142

2005-12-01

Occupational Medicine

Abstract:BACKGROUND Somatization (a tendency to report distress from somatic symptoms) is a little studied, but potentially important, confounder and effect modifier in occupational studies of musculoskeletal disease. AIMS To assess the role of somatization as a risk factor for disabling regional pain. METHODS A questionnaire was mailed to 4998 subjects of working age. Questions were asked about chronic and disabling pain in the past 12 months affecting the arm, low back, knee or combinations of these sites. Distress from physical symptoms was assessed using elements of the Brief Symptom Inventory and mental well-being was assessed using the short-form 36 (SF-36). Associations were examined by modified Cox regression and expressed as hazard ratios (HRs) with 95% confidence intervals (CI). RESULTS Among 2632 responders, 24% reported chronic pain and 25% disabling pain at one or several sites. Risk of chronic or disabling pain increased strongly according to the number of somatic symptoms reported as bothersome. For example, the HR for chronic upper limb pain in those distressed by > or =2 somatic symptoms in the past 7 days versus none was 3.9 (95% CI 2.9-5.3), and that of disabling upper limb pain was 5.8 (95% CI 4.1-8.3). Similar patterns were found for the low back and knee, and there was a gradient of increasing risk according to the number of sites with disabling pain. In comparison, associations with SF-36 mental well-being score were weaker. CONCLUSION Somatizing tendency should be evaluated as a possible confounder or effect modifier in studies of occupational risk factors for musculoskeletal pain.
TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis

Razan Orfali,Ali AlFaiz,Madhawi Alanazi,Rahaf Alabdulsalam,Meaad Alharbi,Yara Alromaih,Ismail Dallak,Marah Alrahal,Abdulaziz Alwatban,Reem Saud

DOI: https://doi.org/10.3390/ijms251910551

IF: 5.6

2024-10-01

International Journal of Molecular Sciences

Abstract:Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in defective chloride ion channels. This leads to thick, dehydrated mucus that severely disrupts mucociliary clearance in the respiratory system and triggers infection that eventually is the cause of death of CF patients. Current therapeutic strategies primarily focus on restoring CFTR function, blocking epithelial sodium channels to prevent mucus dehydration, or directly targeting mucus to reduce its viscosity. Among the ion channels expressed in ciliated bronchial epithelial cells, the transient receptor potential vanilloid 4 (TRPV4) channel emerges as a significant channel in CF pathogenesis. Activation of TRPV4 channels affects the regulation of airway surface liquid by modulating sodium absorption and intracellular calcium levels, which indirectly influences CFTR activity. TRPV4 is also involved in the regulatory volume decrease (RVD) process and enhances inflammatory responses in CF patients. Here, we combine current findings on TRPV4 channel modulation as a promising therapeutic approach for CF. Although limited studies have directly explored TRPV4 in CF, emerging evidence indicates that TRPV4 activation can significantly impact key pathological processes in the disease. Further investigation into TRPV4 modulators could lead to innovative treatments that alleviate severe respiratory complications and improve outcomes for CF patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis

Samar E. Atteih,Catherine R. Armbruster,Yasmin Hilliam,Glenn J. Rapsinski,Junu Koirala Bhusal,Leah L. Krainz,Jordan R. Gaston,Matthew DuPont,Anna C. Zemke,John F. Alcorn,John A. Moore,Vaughn S. Cooper,Stella E. Lee,Erick Forno,Jennifer M. Bomberger

DOI: https://doi.org/10.1002/ppul.26898

IF: 4.0899

2024-02-16

Pediatric Pulmonology

Abstract:Background While the widespread initiation of elexacaftor/tezacaftor/ivacaftor (ETI) has led to dramatic clinical improvements among persons with cystic fibrosis (pwCF), little is known about how ETI affects the respiratory mucosal inflammatory and physiochemical environment, or how these changes relate to lung function. Methods We performed a prospective, longitudinal study of adults with CF and chronic rhinosinusitis (CF‐CRS) followed at our CF center (n = 18). Endoscopic upper respiratory tract (paranasal sinus) aspirates from multiple visit dates, both pre‐ and post‐ETI initiation, were collected and tested for cytokines, metals, pH, and lactate levels. Generalized estimating equations were used to identify relationships between ETI and upper respiratory tract (URT) biomarker levels, and between URT biomarkers and lung function or clinical sinus parameters. Results ETI was associated with decreased upper respiratory mucosal cytokines B‐cell activating factor (BAFF), IL‐12p40, IL‐32, IL‐8, IL‐22 and soluble tumor necrosis factor‐1 (sTNFR1), and an increase in a proliferation‐inducing ligand (APRIL) and IL‐19. ETI was also associated with decreased URT levels of copper, manganese, and zinc. In turn, lower URT levels of BAFF, IL‐8, lactate, and potassium were each associated with ~1.5% to 4.3% improved forced expiratory volume in 1 s (FEV1), while higher levels of IFNγ, iron, and selenium were associated with ~2% to 10% higher FEV1. Conclusions Our observations suggest a dampening of inflammatory signals and restriction in microbial nutrients in the upper respiratory tract with ETI. These findings improve our understanding of how ETI impacts the mucosal environment in the respiratory tract, and may give insight into the improved infectious and inflammatory status and the resulting clinical improvements seen in pwCF.

pediatrics,respiratory system
Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models

Alexandra McCarron,Kak-Ming Ling,Samuel T. Montgomery,Kelly M. Martinovich,Patricia Cmielewski,Nathan Rout-Pitt,Anthony Kicic,David Parsons,Martin Donnelley

DOI: https://doi.org/10.1038/s41434-024-00480-y

2024-08-27

Gene Therapy

Abstract:Mutation-agnostic treatments such as airway gene therapy have the potential to treat any individual with cystic fibrosis (CF), irrespective of their CF transmembrane conductance regulator ( CFTR ) gene variants. The aim of this study was to employ two CF rat models, Phe508del and CFTR knockout (KO), to assess the comparative effectiveness of CFTR modulators and lentiviral (LV) vector-mediated gene therapy. Cells were isolated from the tracheas of rats and used to establish air-liquid interface (ALI) cultures. Phe508del rat ALIs were treated with the modulator combination, elexacaftor-tezacaftor-ivacaftor (ETI), and separate groups of Phe508del and KO tracheal epithelial cells were treated with LV-CFTR followed by differentiation at ALI. Ussing chamber measurements were performed to assess CFTR function. ETI-treated Phe508del ALI cultures demonstrated CFTR function that was 59% of wild-type level, while gene-addition therapy restored Phe508del to 68% and KO to 47% of wild-type level, respectively. Our findings show that rat Phe508del-CFTR protein can be successfully rescued with ETI treatment, and that CFTR gene-addition therapy provides significant CFTR correction in Phe508del and KO ALI cultures to levels that were comparable to ETI. These findings highlight the potential of an LV vector-based gene therapy for the treatment of CF lung disease.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology

GONADAL DYSGENESIS AND HYPOPITUITARISM (DELETION-INDUCED HEMIZYGOSITY).

The 'squeaky wheel' and health care policy.

Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia

Perceptual Comparisons with Pictures and Environmental Sounds

A promoter-dependent upstream activator augments CFTR expression in diverse epithelial cell types

In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells

Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure

More Efficient Tagging Systems with Tag Seeding

Molecular characterization and chromosomal localization of mouse Puralpha gene.

Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome

Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms

The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells

Potentiation of long-acting β2-agonist and glucocorticoid responses in human airway epithelial cells by modulation of intracellular cAMP

Current landscape of cystic fibrosis gene therapy

Disabling musculoskeletal pain and its relation to somatization: a community-based postal survey.

TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis

Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis

Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models